EMERGENT BIOSOLUTIONS INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $149M | ↓-23.6% | — | — | — |
| 2025-09-30 | $231M | ↓-21.3% | $51M | ↓-55.4% | 33.1% |
| 2025-06-30 | $141M | ↓-44.7% | $-12M | ↑+95.8% | 1.1% |
| 2025-03-31 | $222M | ↓-26.0% | $68M | ↑+655.6% | 22.5% |
| 2024-12-31 | $195M | ↓-29.6% | — | — | — |
| 2024-09-30 | $294M | ↑+8.6% | $115M | ↑+143.6% | 22.0% |
| 2024-06-30 | $255M | ↓-24.6% | $-283M | ↓-8.3% | -79.9% |
| 2024-03-31 | $300M | ↑+82.8% | $9M | ↑+104.8% | 13.2% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 63 quarters
margin trajectory tells the operating-leverage storyGo deeper
EBS Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyEBS Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics